title: Terfenadine, astemizole, and ebastine produce QTc interval prolongation in an experimental model predictive of adverse clinical ECG effects.
authors.forename: J A
authors.initials: JA
authors.lastname: Hey
authors.forename: M
authors.initials: M
authors.lastname: del Prado
authors.forename: R W
authors.initials: RW
authors.lastname: Egan
authors.forename: W
authors.initials: W
authors.lastname: Kreutner
mesh_terms: D000818:Animals; D016589:Astemizole / Q000009:adverse effects*; D002090:Butyrophenones / Q000009:adverse effects*; D004562:Electrocardiography / Q000187:drug effects*; D006168:Guinea Pigs; D006634:Histamine H1 Antagonists / Q000009:adverse effects*; D008954:Models, Biological; D010880:Piperidines / Q000009:adverse effects*; D016593:Terfenadine / Q000009:adverse effects*
chemical_list: D002090:Butyrophenones; D006634:Histamine H1 Antagonists; D010880:Piperidines; D016593:Terfenadine; D016589:Astemizole; C058249:ebastine